165 related articles for article (PubMed ID: 7856324)
1. [Effect of clozapine on biogenic amines within the scope of drug treatment of schizophrenic psychoses in adolescence].
Schulz E; Remschmidt H; Fleischhaker C
Z Kinder Jugendpsychiatr; 1994 Dec; 22(4):285-98. PubMed ID: 7856324
[TBL] [Abstract][Full Text] [Related]
2. [Depressive symptoms and biogenic amines as predictors of treatment response in schizophrenic illnesses in childhood and adolescence].
Fleischhaker C; Schulz E; Remschmidt H
Z Kinder Jugendpsychiatr Psychother; 1998 Dec; 26(4):235-43. PubMed ID: 9880833
[TBL] [Abstract][Full Text] [Related]
3. Biogenic amines as predictors of response to clozapine treatment in early-onset schizophrenia.
Fleischhaker C; Schulz E; Remschmidt H
J Psychiatr Res; 1998; 32(5):325-33. PubMed ID: 9789212
[TBL] [Abstract][Full Text] [Related]
4. Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia.
Schulz E; Fleischhaker C; Remschmidt HE
J Child Adolesc Psychopharmacol; 1996; 6(2):119-31. PubMed ID: 9231304
[TBL] [Abstract][Full Text] [Related]
5. Blood biogenic amines during clozapine treatment of early-onset schizophrenia.
Schulz E; Fleischhaker C; Clement HW; Remschmidt H
J Neural Transm (Vienna); 1997; 104(10):1077-89. PubMed ID: 9503259
[TBL] [Abstract][Full Text] [Related]
6. [Follow-up dynamics of schizophrenic diseases in adolescence].
Schulz E; Martin M; Remschmidt H
Z Kinder Jugendpsychiatr; 1994 Dec; 22(4):262-74. PubMed ID: 7856322
[TBL] [Abstract][Full Text] [Related]
7. Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study.
Gross A; Joutsiniemi SL; Rimon R; Appelberg B
Pharmacopsychiatry; 2004 May; 37(3):119-22. PubMed ID: 15138895
[TBL] [Abstract][Full Text] [Related]
8. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.
Henderson DC; Goff DC
J Clin Psychiatry; 1996 Sep; 57(9):395-7. PubMed ID: 9746446
[TBL] [Abstract][Full Text] [Related]
9. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
Nagaoka S; Iwamoto N; Arai H
Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
[TBL] [Abstract][Full Text] [Related]
10. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
[TBL] [Abstract][Full Text] [Related]
11. [Presentation of obsessive-compulsive symptoms in a patient with schizophrenia treated with clozapine].
Stengler-Wenzke K
Psychiatr Prax; 1999 May; 26(3):145-6. PubMed ID: 10412713
[TBL] [Abstract][Full Text] [Related]
12. Lower levels of whole blood serotonin in obsessive-compulsive disorder and in schizophrenia with obsessive-compulsive symptoms.
Ma N; Tan LW; Wang Q; Li ZX; Li LJ
Psychiatry Res; 2007 Feb; 150(1):61-9. PubMed ID: 17291595
[TBL] [Abstract][Full Text] [Related]
13. [Clozapine and treatment of negative symptoms].
Lançon C; Farisse J; Llorca PM
Encephale; 1997 Sep; 23 Spec No 4():7-11. PubMed ID: 9417403
[TBL] [Abstract][Full Text] [Related]
14. Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia.
Oades RD; Klimke A; Henning U; Rao ML
Hum Psychopharmacol; 2002 Jan; 17(1):15-27. PubMed ID: 12404703
[TBL] [Abstract][Full Text] [Related]
15. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study.
Dursun SM; Szemis A; Andrews H; Reveley MA
J Psychiatry Neurosci; 1999 Nov; 24(5):453-5. PubMed ID: 10586536
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Zink M; Kuwilsky A; Krumm B; Dressing H
J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
[TBL] [Abstract][Full Text] [Related]
17. [Long-term clinical experience with clozapine].
Gelly F; Chambon O; Marie-Cardine M
Encephale; 1997; 23(5):385-96. PubMed ID: 9453932
[TBL] [Abstract][Full Text] [Related]
18. [Clozapine and refractory schizophrenia. Long-term prospective study of 20 patients].
Jalenques I; Coudert AJ
Encephale; 1994; 20(6):767-75. PubMed ID: 7875111
[TBL] [Abstract][Full Text] [Related]
19. Predictors of clinical outcome in schizophrenic patients responding to clozapine.
Mauri MC; Volonteri LS; Dell'Osso B; Regispani F; Papa P; Baldi M; Bareggi SR
J Clin Psychopharmacol; 2003 Dec; 23(6):660-4. PubMed ID: 14624196
[TBL] [Abstract][Full Text] [Related]
20. Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.
Zink M; Knopf U; Henn FA; Thome J
Pharmacopsychiatry; 2004 Jan; 37(1):26-31. PubMed ID: 14750045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
